Highlights for the Quarter Y-O-Y:
• Revenue at ₹2,631 million, a growth of 12%
• Domestic Sales grew by 19%
• EPS grew by INR 5.95 (22%), driven by increase in revenue
• Profit Before Tax was up by 22%
Highlights for the nine months ended ’26 Y-O-Y:
• Revenue from Operations at ₹7,280 million, a growth of 16%
• Domestic Sales grew by 15%; aided by relaunch
• Export Sales grew by 19%
• Profit Before Tax was up by 24%
Chennai: Sanofi Consumer Healthcare India Limited (BSE:544250 I NSE: SANOFICONR) releases its financial results for the third quarter and nine months ended 2026, demonstrating profitable growth across key business segments. Revenue growth for the quarter stood at 12% year-on-year with domestic sales growing by 19%. Profit Before Tax (PBT) for Q3 ‘26 reached ₹1,027 million, an increase of 22% on a year-on-year basis. EPS grew by 22% year-on-year, supported by higher revenue and profitability during the quarter.
Commenting on the results, Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited, “Our Q3 performance reflects the disciplined execution of our strategy and the strength of our portfolio. We delivered healthy growth, driven by volume expansion and market share gains across key brands. Our investments in brand building and expanding our distribution footprint and Healthcare Professional reach are enabling us to serve more consumers.
****